- Previous Close
72.80 - Open
72.80 - Bid 71.00 x --
- Ask 72.00 x --
- Day's Range
70.40 - 74.60 - 52 Week Range
49.20 - 90.60 - Volume
39,652 - Avg. Volume
25,028 - Market Cap (intraday)
2.081B - Beta (5Y Monthly) 0.59
- PE Ratio (TTM)
61.72 - EPS (TTM)
1.16 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
77.50
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.
www.eqlpharma.com28
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: EQL.ST
View MorePerformance Overview: EQL.ST
Trailing total returns as of 3/19/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EQL.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EQL.ST
View MoreValuation Measures
Market Cap
2.12B
Enterprise Value
2.26B
Trailing P/E
62.76
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.27
Price/Book (mrq)
10.17
Enterprise Value/Revenue
6.67
Enterprise Value/EBITDA
42.77
Financial Highlights
Profitability and Income Statement
Profit Margin
10.26%
Return on Assets (ttm)
8.24%
Return on Equity (ttm)
18.23%
Revenue (ttm)
338.39M
Net Income Avi to Common (ttm)
34.73M
Diluted EPS (ttm)
1.16
Balance Sheet and Cash Flow
Total Cash (mrq)
15.56M
Total Debt/Equity (mrq)
75.50%
Levered Free Cash Flow (ttm)
-70.88M